ID   MDA-MB-435
AC   CVCL_0417
SY   MDA-MB435; MDAMB435; MDA.MB.435; MDA-435; MDA 435; MDA435; MD Anderson-Metastatic Breast-435
DR   BTO; BTO:0001567
DR   EFO; EFO_0001213
DR   MCCL; MCC:0000314
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-TABM-157
DR   BioSample; SAMN03151832
DR   BioSample; SAMN03470861
DR   cancercelllines; CVCL_0417
DR   Cell_Model_Passport; SIDM00004
DR   ChEMBL-Cells; CHEMBL3307686
DR   ChEMBL-Targets; CHEMBL614697
DR   Cosmic; 687496
DR   Cosmic; 875879
DR   Cosmic; 905988
DR   Cosmic; 974069
DR   Cosmic; 974236
DR   Cosmic; 991325
DR   Cosmic; 1000131
DR   Cosmic; 1010930
DR   Cosmic; 1044219
DR   Cosmic; 1092614
DR   Cosmic; 1175834
DR   Cosmic; 1176643
DR   Cosmic; 1219445
DR   Cosmic; 1305366
DR   Cosmic; 1312349
DR   Cosmic; 1477425
DR   Cosmic; 1524346
DR   Cosmic; 1571794
DR   Cosmic; 1945861
DR   Cosmic; 1998456
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM2095
DR   GEO; GSM50203
DR   GEO; GSM50265
DR   GEO; GSM206523
DR   GEO; GSM274648
DR   GEO; GSM274649
DR   GEO; GSM344352
DR   GEO; GSM344402
DR   GEO; GSM383801
DR   GEO; GSM383802
DR   GEO; GSM383803
DR   GEO; GSM743466
DR   GEO; GSM750814
DR   GEO; GSM783965
DR   GEO; GSM799354
DR   GEO; GSM799417
DR   GEO; GSM844589
DR   GEO; GSM844590
DR   GEO; GSM847037
DR   GEO; GSM1008908
DR   GEO; GSM1153424
DR   GEO; GSM1178391
DR   GEO; GSM1178392
DR   GEO; GSM1181294
DR   GEO; GSM1181337
DR   GEO; GSM1215267
DR   GEO; GSM1670084
DR   GEO; GSM2124670
DR   IARC_TP53; 18065
DR   NCI-DTP; MDA-MB-435
DR   PharmacoDB; MDAMB435_904_2019
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   Progenetix; CVCL_0417
DR   PubChem_Cell_line; CVCL_0417
DR   SKY/M-FISH/CGH; 2816
DR   TOKU-E; 3544
DR   Wikidata; Q50952937
RX   CelloPub=CLPUB00423;
RX   DOI=10.4172/2157-7145.S2-005;
RX   PubMed=730202;
RX   PubMed=7272986;
RX   PubMed=10700174;
RX   PubMed=10969801;
RX   PubMed=11044355;
RX   PubMed=15153330;
RX   PubMed=15748285;
RX   PubMed=17004106;
RX   PubMed=17088437;
RX   PubMed=17157791;
RX   PubMed=18304946;
RX   PubMed=19372543;
RX   PubMed=19549886;
RX   PubMed=20143388;
RX   PubMed=20164919;
RX   PubMed=22068913;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22628656;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24094812;
RX   PubMed=24162158;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28721362;
RX   PubMed=28889351;
RX   PubMed=28940260;
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://dtp.cancer.gov/discovery_development/nci-60/mda-mb-435.htm
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=51
WW   https://www.cellosaurus.org/pawefish/BreastCellLineDescriptions/mda-mb-435.htm
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
WW   https://www.ncbi.nlm.nih.gov/pubmed/25902968#cm25902968_13561
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
CC   Problematic cell line: Contaminated. Shown to be a M14 derivative (PubMed=17004106; PubMed=18304946; PubMed=20143388; PubMed=28940260). Originally thought to originate from the pleural effusion of a breast carcinoma from a 31 year old patient. See also PubMed=19549886 for a dissenting but incorrect view that states that M14 is a breast cancer cell line.
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: NCI-60 cancer cell line panel.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00235.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12583.
CC   Population: Caucasian.
CC   Doubling time: 25.8 hours (NCI-DTP=MDA-MB-435); 38.72 hours (GrayJW panel).
CC   HLA typing: A*11:01:01,24:02:01; B*15,35; C*03:03:01,04; DPB1*13:01,19:01; DQB1*03:02,06:03; DRB1*04:05:01,13:01:01 (PubMed=15748285).
CC   HLA typing: A*24:02,24:02; B*15:01,15:01; C*03:03,03:03; DQA1*01:03,01:03; DQB1*06:03,06:03; DRB1*03:17,13:01 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17088437; PubMed=28889351).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=17088437; PubMed=28889351).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).
CC   Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000351). It was one of the sources for the STR profile of this entry.
CC   Misspelling: MDA-MB-43; Note=Occasionally.
CC   Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072.
ST   Source(s): CCRID; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200; PubMed=28889351
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 13
ST   D18S51: 13 (PubMed=25877200)
ST   D18S51: 13,17 (CCRID; DOI=10.4172/2157-7145.S2-005; PubMed=19372543)
ST   D19S433: 14 (CCRID; DOI=10.4172/2157-7145.S2-005; PubMed=25877200)
ST   D19S433: 14,15 (PubMed=19372543)
ST   D21S11: 29,31.2 (PubMed=28889351)
ST   D21S11: 30 (CCRID; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200)
ST   D2S1338: 19,24
ST   D3S1358: 14
ST   D5S818: 11,12 (CCRID; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=28889351)
ST   D5S818: 12 (PubMed=25877200)
ST   D7S820: 8,10
ST   D8S1179: 13
ST   FGA: 21
ST   Penta D: 9,11
ST   Penta E: 10,12
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1395 ! M14
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 40
//
RX   CelloPub=CLPUB00423;
RA   Morrison B.J.;
RT   "Breast cancer stem cells: tumourspheres and implications for therapy.";
RL   Thesis PhD (2010), Griffith University, Australia.
//
RX   DOI=10.4172/2157-7145.S2-005;
RA   Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.,
RA   Hart R.P., Furtado M.R.;
RT   "STR profiling of human cell lines: challenges and possible solutions
RT   to the growing problem.";
RL   J. Forensic Res. 2 Suppl. 2:5-5(2011).
//
RX   PubMed=730202; DOI=10.1007/BF02616120;
RA   Cailleau R.M., Olive M., Cruciger Q.V.J.;
RT   "Long-term human breast carcinoma cell lines of metastatic origin:
RT   preliminary characterization.";
RL   In Vitro 14:911-915(1978).
//
RX   PubMed=7272986; DOI=10.1016/0165-4608(81)90057-1;
RA   Satya-Prakash K.L., Pathak S., Hsu T.-C., Olive M., Cailleau R.M.;
RT   "Cytogenetic analysis on eight human breast tumor cell lines: high
RT   frequencies of 1q, 11q and HeLa-like marker chromosomes.";
RL   Cancer Genet. Cytogenet. 3:61-73(1981).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=10969801;
RA   Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y.,
RA   Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.;
RT   "Comparative genomic hybridization analysis of 38 breast cancer cell
RT   lines: a basis for interpreting complementary DNA microarray data.";
RL   Cancer Res. 60:4519-4525(2000).
//
RX   PubMed=11044355; DOI=10.1054/bjoc.2000.1458;
RA   Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C.,
RA   Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.;
RT   "Molecular cytogenetic analysis of breast cancer cell lines.";
RL   Br. J. Cancer 83:1309-1317(2000).
//
RX   PubMed=15153330; DOI=10.1593/neo.3292;
RA   Watts G.S., Oshiro M.M., Junk D.J., Wozniak R.J., Watterson S.J.,
RA   Domann F.E., Futscher B.W.;
RT   "The acetyltransferase p300/CBP-associated factor is a p53 target gene
RT   in breast tumor cells.";
RL   Neoplasia 6:187-194(2004).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
//
RX   PubMed=17004106; DOI=10.1007/s10549-006-9392-8;
RA   Rae J.M., Creighton C.J., Meck J.M., Haddad B.R., Johnson M.D.;
RT   "MDA-MB-435 cells are derived from M14 melanoma cells -- a loss for
RT   breast cancer, but a boon for melanoma research.";
RL   Breast Cancer Res. Treat. 104:13-19(2007).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=18304946; DOI=10.1093/nar/gkn089;
RA   Demichelis F., Greulich H., Macoska J.A., Beroukhim R., Sellers W.R.,
RA   Garraway L.A., Rubin M.A.;
RT   "SNP panel identification assay (SPIA): a genetic-based assay for the
RT   identification of cell lines.";
RL   Nucleic Acids Res. 36:2446-2456(2008).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=19549886; DOI=10.1158/0008-5472.CAN-09-1528;
RA   Chambers A.F.;
RT   "MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?";
RL   Cancer Res. 69:5292-5293(2009).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C.,
RA   Wilhelm M., Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24162158; DOI=10.1007/s10549-013-2743-3;
RA   Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M.,
RA   Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.;
RT   "Characterization of cell lines derived from breast cancers and normal
RT   mammary tissues for the study of the intrinsic molecular subtypes.";
RL   Breast Cancer Res. Treat. 142:237-255(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
//
RX   PubMed=28721362; DOI=10.1038/npjbcancer.2015.2;
RA   Prasad V.V.T.S., Gopalan R.O.G.;
RT   "Continued use of MDA-MB-435, a melanoma cell line, as a model for
RT   human breast cancer, even in year, 2014.";
RL   NPJ Breast Cancer 1:15002.1-15002.2(2015).
//
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).
//
RX   PubMed=28940260; DOI=10.1002/ijc.31067;
RA   Korch C.T., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M.,
RA   Robinson S., Storts D.R., Turner J.A., Wang Y., Burnett E.C.,
RA   Healy L.E., Kniss D.A., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A.,
RA   Capes-Davis A.;
RT   "Authentication of M14 melanoma cell line proves misidentification of
RT   MDA-MB-435 breast cancer cell line.";
RL   Int. J. Cancer 142:561-572(2017).
//